Effectiveness
Patients experienced significant improvement in disease severity by multiple measures as early as week 4, with further improvements by week 28. The PASI score decreased from a mean ± SD of 11.6 ± 7.1 (median, 10.5; range, 2.7 to 33.8) at baseline to 6.5 ± 5.1 at week 4 (mean percent improvement, 45.3%; P<0.001) and to 1.8 ± 3.0 at week 28 (mean percent improvement, 82.1%; P<0.001; Figure 1A–B). At week 28, the PASI 75 response rate was 76.9%, the PASI 90 response rate was 55.8%, and the PASI 100 response rate was 21.2% (Figure 1C–E).
Mean ± SD BSA decreased from 14.5 ± 11.5 at baseline to 11.6 ± 10.6 at week 4 (mean percent improvement, 21.6%) and further decreased to 2.9 ± 6.4 by week 28 (mean percent improvement, 73.1%; both P<0.001; Figure 2A–C). The mean ± SD sPGA was 3.2 ± 0.6 at baseline and decreased to 2.1 ± 0.7 by week 4 (mean percent improvement, 33.9%; P< 0.001) and to 1.2 ± 0.9 by week 28 (mean percent improvement, 61.7%; P<0.001; Figure 3A–C). The mean (± SD) calculated sPGA x BSA decreased from 47.0 ± 41.5 at baseline to 26.0 ± 26.2 at week 4 (mean percent improvement, 43.9%; P<0.001) and to 6.8 ± 20.3 at week 28 (mean percent improvement, 80.1%; P<0.001; Figure 4A–C).
